Although bisphosphonates have been used for many years, denosumab, the first complete human IgG2 monoclonal antibody for RANKL, has been clinically approved for treating bone-related cancer pathologies and is being used increasingly in clinics (Rizzoli et al., 2010). Here, TNFSF11 is linked to cancer.